Equities analysts expect Corvus Pharmaceuticals (NASDAQ:CRVS) to post earnings of ($0.71) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Corvus Pharmaceuticals’ earnings. Corvus Pharmaceuticals posted earnings of ($0.79) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 10.1%. The firm is expected to issue its next earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that Corvus Pharmaceuticals will report full year earnings of ($3.16) per share for the current financial year, with EPS estimates ranging from ($3.22) to ($3.09). For the next year, analysts expect that the company will post earnings of ($2.93) per share. Zacks’ earnings per share averages are an average based on a survey of research firms that follow Corvus Pharmaceuticals.
Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its earnings results on Thursday, March 1st. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.18.
CRVS has been the topic of a number of research analyst reports. Zacks Investment Research lowered Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. Cowen reissued a “buy” rating on shares of Corvus Pharmaceuticals in a research report on Friday, March 2nd. Finally, ValuEngine downgraded shares of Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company’s stock. Corvus Pharmaceuticals has a consensus rating of “Hold” and an average price target of $18.67.
Shares of NASDAQ CRVS opened at $10.47 on Thursday. Corvus Pharmaceuticals has a 52-week low of $7.42 and a 52-week high of $17.64.
In other Corvus Pharmaceuticals news, CEO Richard A. Md Miller purchased 100,000 shares of the company’s stock in a transaction on Monday, March 12th. The stock was acquired at an average price of $8.50 per share, for a total transaction of $850,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Adams Street Partners Llc purchased 588,235 shares of the company’s stock in a transaction on Monday, March 12th. The stock was acquired at an average price of $8.50 per share, with a total value of $4,999,997.50. Following the purchase, the insider now owns 4,420,516 shares of the company’s stock, valued at $37,574,386. The disclosure for this purchase can be found here. Insiders own 46.40% of the company’s stock.
Several large investors have recently bought and sold shares of CRVS. SG Americas Securities LLC acquired a new position in shares of Corvus Pharmaceuticals during the fourth quarter worth $150,000. California State Teachers Retirement System grew its stake in shares of Corvus Pharmaceuticals by 121.2% during the second quarter. California State Teachers Retirement System now owns 14,967 shares of the company’s stock worth $181,000 after purchasing an additional 8,200 shares in the last quarter. Deutsche Bank AG grew its stake in shares of Corvus Pharmaceuticals by 118.1% during the fourth quarter. Deutsche Bank AG now owns 19,058 shares of the company’s stock worth $196,000 after purchasing an additional 10,320 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of Corvus Pharmaceuticals during the fourth quarter worth $253,000. Finally, Spark Investment Management LLC acquired a new position in shares of Corvus Pharmaceuticals during the fourth quarter worth $295,000. Institutional investors and hedge funds own 82.71% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thelincolnianonline.com/2018/04/17/0-71-eps-expected-for-corvus-pharmaceuticals-crvs-this-quarter.html.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.